

**In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030**

Market Report | 2025-05-09 | 740 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global In vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. This is due to the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases (e.g., HIV, tuberculosis). Demand for faster results, decentralized testing, and home-based diagnostics are pushing growth in point-of-care (POC) testing devices, innovations such as high-throughput systems, lab-on-a-chip, next-generation sequencing (NGS), and POC diagnostics, and government and private sector investments in healthcare infrastructure, especially in developing economies, are improving access to diagnostic services. The reagents & kits segment is expected to grow at the highest CAGR during the forecast period.

Based on the product, the in vitro diagnostics market is divided into reagents & kits, instruments, and data management software & services. In 2024, the reagents & kits segment grew at the highest CAGR in vitro diagnostics market. This is due to the growing number of tests across hospitals, labs, and home settings, the expansion of rapid and self-testing kits, especially for glucose, pregnancy, and infectious disease detection, the expansion of clinical laboratories, diagnostic chains, and POC testing environments increases reagent usage. Continuous product launches and regulatory approvals-such as CE-IVD marking and FDA clearances-are expanding the portfolio and accessibility of specialized test kits across various clinical applications.

The infectious diseases segment of the in vitro diagnostics market, by application, is expected to hold the largest market share during the forecast period.

Based on application, the in vitro diagnostics market is segmented into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostic, drug monitoring & testing, bone & mineral disorders,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

coagulation testing, blood group typing, and other applications. The infectious disease segment accounts for the largest market share of the in vitro diagnostics market due to the continued prevalence of diseases such as HIV, hepatitis, and tuberculosis, and emerging threats such as Malaria and Mpox, the need for fast, accessible testing-especially in remote or resource-limited settings-has boosted the adoption of portable and easy-to-use IVD kits for infectious diseases, and technologies such as RT-PCR (Reverse transcription polymerase chain reaction) and syndromic panel testing enable accurate, high-throughput diagnosis of multiple pathogens, driving growth in hospital and lab settings.

Asia Pacific is expected to hold the highest CAGR in the in vitro diagnostics market during the forecast period.

The global in vitro diagnostics market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The IVD market in the Asia Pacific region is growing rapidly due to the increasing prevalence of communicable and non-communicable diseases, especially in highly populated countries such as China and India. These countries are seeing a rise in conditions such as diabetes, cancer, cardiovascular diseases, tuberculosis, and hepatitis. Concurrently, the aging population is driving the IVD market in the Asia Pacific region, especially in Japan, South Korea, and China. For instance, within China, 216.76 million people are aged 65 and above, or 15.4% of the population, a 2023 report by China's Ministry of Civil Affairs and the China National Committee on Aging stated. This trend is resulting in a growing demand for chronic disease monitoring and regular diagnostics. In an effort to increase local production and decrease the reliance on imports, regional governments are promoting the manufacture of diagnostic reagents, kits, and equipment locally, thus also fuelling the growth of the market.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1- 42%, Tier 2- 30%, and Tier 3- 28%

-□By Designation: C-level- 46%, Director level- 23%, and Others- 31%

-□By Region: North America- 23%, Europe- 45%, Asia Pacific- 28%, Latin America- 3%, Middle East & Africa- 0.5%, and GCC Countries- 0.5 %

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the in vitro diagnostics market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMérieux (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Germany), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation, (US) among others.

#### Research Coverage

This report studies the in vitro diagnostics market based on product & service, technology, specimen, site of testing, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions).

#### Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This report provides insights on the following points:

- Analysis of key drivers (Increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid PoC technologies and rising adoption of automated analyzers, growing preference for personalized medicines), restraints (Unfavorable reimbursement scenario, stringent regulatory requirements, High cost of diagnostic equipment), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, Improvements in immunoassay diagnostic technologies, digitalization trend), challenges (operational barriers, data privacy, and cybersecurity risks)
- Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the in vitro diagnostics market
- Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the in vitro diagnostics market
- Market Development: Complete knowledge about profitable developing regions
- Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the in vitro diagnostics industry helps to diversify the market
- Competitive Assessment: Comprehensive evaluation of market segmentation, development plans, income analysis, and goods of the top market participants

## **Table of Contents:**

1□INTRODUCTION□	57
1.1□STUDY OBJECTIVES□	57
1.2□MARKET DEFINITION□	57
1.3□STUDY SCOPE□	58
1.3.1□MARKETS COVERED AND REGIONAL SCOPE□	58
1.3.2□INCLUSIONS AND EXCLUSIONS□	59
1.3.3□YEARS CONSIDERED□	60
1.4□CURRENCY CONSIDERED□	60
1.5□STAKEHOLDERS□	61
1.6□SUMMARY OF CHANGES□	61
2□RESEARCH METHODOLOGY□	62
2.1□RESEARCH DATA□	62
2.1.1□SECONDARY RESEARCH□	63
2.1.1.1□Key data from secondary sources□	64
2.1.2□PRIMARY DATA□	65
2.1.2.1□Primary sources□	65
2.1.2.2□Key data from primary sources□	66
2.1.2.3□Key industry insights□	67
2.2□MARKET SIZE ESTIMATION□	68
2.2.1□BOTTOM-UP APPROACH□	69
2.2.1.1□Approach 1: Company revenue estimation approach□	69
2.2.1.2□Approach 2: Presentations of companies and primary interviews□	70
2.2.1.3□Growth forecast□	70
2.2.2□TOP-DOWN APPROACH□	71
2.3□MARKET BREAKDOWN AND DATA TRIANGULATION□	72
2.4□MARKET SHARE ANALYSIS□	73
2.5□RESEARCH ASSUMPTIONS□	73
2.5.1□PARAMETRIC ASSUMPTIONS□	73

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.5.2	GROWTH RATE ASSUMPTIONS	74
2.6	RESEARCH LIMITATIONS	74
2.7	RISK ASSESSMENT	74
3	EXECUTIVE SUMMARY	75
?		
4	PREMIUM INSIGHTS	82
4.1	IN VITRO DIAGNOSTICS MARKET OVERVIEW	82
4.2	NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024	83
4.3	IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	84
4.4	IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX	84
4.5	IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS	85
5	MARKET OVERVIEW	86
5.1	INTRODUCTION	86
5.2	MARKET DYNAMICS	86
5.2.1	DRIVERS	87
5.2.1.1	Increasing geriatric population and subsequent rise in chronic diseases	87
5.2.1.2	Growing awareness of early disease diagnosis in emerging economies	88
5.2.1.3	Emergence of rapid PoC technologies and rising adoption of automated analyzers	89
5.2.1.4	Growing preference for personalized medicines	89
5.2.2	RESTRAINTS	90
5.2.2.1	Unfavorable reimbursement scenario	90
5.2.2.2	Stringent regulatory requirements	90
5.2.2.3	High cost of diagnostic equipment	92
5.2.3	OPPORTUNITIES	92
5.2.3.1	Introduction of disease-specific biomarkers and tests	92
5.2.3.2	Increasing significance of companion diagnostics	93
5.2.3.3	Growth opportunities in developing countries	94
5.2.3.4	Improvements in immunoassay diagnostic technologies	95
5.2.3.5	Digitalization trend	96
5.2.4	CHALLENGES	96
5.2.4.1	Operational barriers	96
5.2.4.2	Data privacy and cybersecurity risks	97
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	98
5.4	PRICING ANALYSIS	98
5.4.1	AVERAGE SELLING PRICE TREND, BY KEY PLAYER	98
5.4.2	AVERAGE SELLING PRICE TREND, BY REGION	100
5.4.3	AVERAGE SELLING PRICE TREND, BY PRODUCT	100
5.5	VALUE CHAIN ANALYSIS	102
5.5.1	RESEARCH & DEVELOPMENT	102
5.5.2	RAW MATERIAL SUPPLIERS	102
5.5.3	MANUFACTURING	102
5.5.4	DISTRIBUTION, MARKETING, AND SALES	102
5.5.5	RETAILERS	102
5.5.6	POST-SALES SERVICES	102
5.6	SUPPLY CHAIN ANALYSIS	103
5.6.1	PROMINENT COMPANIES	103
5.6.2	SMALL & MEDIUM-SIZED ENTERPRISES	104

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6.3	END USERS	104
5.7	ECOSYSTEM ANALYSIS	104
5.8	INVESTMENT AND FUNDING SCENARIO	106
5.9	TECHNOLOGY ANALYSIS	107
5.9.1	KEY TECHNOLOGIES	107
5.9.2	COMPLEMENTARY TECHNOLOGIES	108
5.9.2.1	Immunohistochemistry	108
5.10	PATENT ANALYSIS	109
5.11	TRADE ANALYSIS	111
5.11.1	IMPORT DATA FOR HS CODE 382200	111
5.11.2	EXPORT DATA FOR HS CODE 382200	112
5.12	KEY CONFERENCES AND EVENTS, 2025-2026	112
5.13	CASE STUDY ANALYSIS	113
5.13.1	CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE	113
5.13.2	CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET	114
5.13.3	CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING	115
5.14	REGULATORY LANDSCAPE	115
5.14.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	116
5.15	REGULATORY FRAMEWORK	118
5.15.1	NORTH AMERICA	118
5.15.1.1	US	118
5.15.1.2	Canada	120
5.15.2	EUROPE	120
5.15.3	ASIA PACIFIC	122
5.15.3.1	Japan	122
5.15.3.2	China	123
5.15.3.3	India	124
5.15.3.4	South Korea	124
5.15.3.5	Indonesia	125
5.15.3.6	Russia	126
5.15.4	MIDDLE EAST & AFRICA	126
5.15.4.1	Saudi Arabia	126
5.15.4.2	Africa	127
5.15.5	LATIN AMERICA	127
5.15.5.1	Mexico	127
5.15.5.2	Brazil	128
5.16	PORTER'S FIVE FORCES ANALYSIS	128
5.16.1	BARGAINING POWER OF SUPPLIERS	130
5.16.2	BARGAINING POWER OF BUYERS	130
5.16.3	THREAT OF NEW ENTRANTS	130
5.16.4	THREAT OF SUBSTITUTES	130
5.16.5	INTENSITY OF COMPETITIVE RIVALRY	130
5.17	KEY STAKEHOLDERS AND BUYING CRITERIA	131
5.17.1	KEY STAKEHOLDERS IN BUYING PROCESS	131
5.17.2	BUYING CRITERIA	132
5.18	RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS	133

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.19	INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES	135
5.20	GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING	136
5.21	IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET	138
5.21.1	INTRODUCTION	138
5.21.2	MARKET POTENTIAL OF AI IN IVD DEVICES	138
5.21.3	AI USE CASES	139
5.21.4	KEY COMPANIES IMPLEMENTING AI	140
5.21.5	FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET	140
6	IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE	141
6.1	INTRODUCTION	142
6.2	REAGENTS & KITS	142
6.2.1	RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH	142
6.3	INSTRUMENTS	146
6.3.1	GROWING TREND OF AUTOMATION TO DRIVE MARKET	146
6.4	DATA MANAGEMENT SOFTWARE & SERVICES	151
6.4.1	INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH	151
7	IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY	156
7.1	INTRODUCTION	157
7.2	IMMUNOASSAYS	157
7.2.1	ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)	162
7.2.1.1	Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth	162
7.2.2	CHEMILUMINESCENCE IMMUNOASSAYS	166
7.2.2.1	Need for minimal human intervention to support growth	166
7.2.3	IMMUNOFLUORESCENCE ASSAYS	171
7.2.3.1	Growing introduction of innovative diagnostic platforms to drive market	171
7.2.4	RAPID TESTS	174
7.2.4.1	Need for rapid diagnostic tests to expedite growth	174
7.2.5	ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)	178
7.2.5.1	Need for early detection and monitoring of immune-related disorders to amplify growth	178
7.2.6	WESTERN BLOTTING	182
7.2.6.1	Increasing focus on biomarker discovery and personalized treatment to advance growth	182
7.2.7	OTHER IMMUNOASSAY TECHNOLOGIES	185
7.3	CLINICAL CHEMISTRY	188
7.3.1	BASIC METABOLIC PANELS	194
7.3.1.1	Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth	194
7.3.2	LIVER PANELS	197
7.3.2.1	Rising prevalence of cirrhosis and viral hepatitis to foster growth	197
7.3.3	RENAL PROFILES	201
7.3.3.1	Growing awareness for preventive health check-ups to boost market	201
7.3.4	LIPID PROFILES	204
7.3.4.1	Rising prevalence of obesity to accelerate growth	204
7.3.5	THYROID FUNCTION PROFILES	208
7.3.5.1	High incidence of thyroid-related disorders to support growth	208
7.3.6	ELECTROLYTE PANELS	211
7.3.6.1	Growing shift toward home care and remote patient monitoring to fuel market	211
7.3.7	SPECIALTY CHEMICAL TESTS	215
7.3.7.1	Rising demand for specialized tests to contribute to growth	215

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

7.4	MOLECULAR DIAGNOSTICS	218
7.4.1	POLYMERASE CHAIN REACTION	223
7.4.1.1	High accuracy and speed in detecting pathogens to aid growth	223
7.4.2	ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY	227
7.4.2.1	Growing focus on rapid, onsite molecular diagnostics to propel market	227
7.4.3	DNA SEQUENCING & NEXT-GENERATION SEQUENCING	231
7.4.3.1	Growing applications in research, drug discovery, and molecular diagnostics to boost market	231
7.4.4	IN SITU HYBRIDIZATION	235
7.4.4.1	Rising prevalence of cancer and genetic disorders to assist growth	235
7.4.5	DNA MICROARRAYS	238
7.4.5.1	High resolution and throughput capabilities to favor growth	238
7.4.6	OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES	241
7.5	GLUCOSE MONITORING	244
7.5.1	ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH	244
7.6	HEMATOLOGY	248
7.6.1	GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET	248
7.7	MICROBIOLOGY	251
7.7.1	RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH	251
7.8	COAGULATION & HEMOSTASIS	254
7.8.1	GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET	254
7.9	BLOOD GAS ANALYZERS	258
7.9.1	GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET	258
7.10	URINALYSIS	262
7.10.1	RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH	262
7.11	CHROMATOGRAPHY & MASS SPECTROMETRY	265
7.11.1	INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH	265
8	IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN	270
8.1	INTRODUCTION	271
8.2	BLOOD, SERUM, AND PLASMA SPECIMENS	271
8.2.1	GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET	271
8.3	SALIVA SPECIMENS	275
8.3.1	GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET	275
8.4	URINE SPECIMENS	278
8.4.1	RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH	278
8.5	OTHER SPECIMENS	282
9	IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING	286
9.1	INTRODUCTION	287
9.2	LABORATORY TESTS	287
9.2.1	INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH	287
9.3	POINT-OF-CARE TESTS	293
9.3.1	RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH	293
10	IN VITRO DIAGNOSTICS MARKET, BY APPLICATION	299
10.1	INTRODUCTION	300
10.2	INFECTIOUS DISEASES	301
10.2.1	INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH	301
10.3	ONCOLOGY	304

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.1	INCREASING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH	304
10.4	ENDOCRINOLOGY	308
10.4.1	INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH	308
10.5	CARDIOLOGY	312
10.5.1	GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET	312
10.6	BLOOD SCREENING	315
10.6.1	INCREASING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH	315
10.7	GENETIC TESTING	319
10.7.1	INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH	319
10.8	AUTOIMMUNE DISEASES	322
10.8.1	RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH	322
10.9	ALLERGY DIAGNOSTICS	326
10.9.1	INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH	326
10.10	DRUG MONITORING & TESTING	330
10.10.1	INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH	330
10.11	BONE & MINERAL DISORDERS	334
10.11.1	INCREASING CASES OF OSTEOPOROSIS TO FUEL MARKET	334
10.12	COAGULATION TESTING	338
10.12.1	INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH	338
10.13	BLOOD GROUP TYPING	341
10.13.1	INCREASING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH	341
10.14	OTHER APPLICATIONS	345
11	IN VITRO DIAGNOSTICS MARKET, BY END USER	349
11.1	INTRODUCTION	350
11.2	HOSPITALS & CLINICS	350
11.2.1	EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH	350
11.3	CLINICAL LABORATORIES	354
11.3.1	LARGE REFERENCE LABORATORIES	358
11.3.1.1	Growing test volume and complexity of diagnostic testing to propel market	358
11.3.2	SMALL AND MEDIUM-SIZED LABORATORIES	361
11.3.2.1	Increasing shift toward community-based and point-of-care settings to foster growth	361
11.4	BLOOD BANKS	364
11.4.1	NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH	364
11.5	HOME CARE SETTINGS	368
11.5.1	GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET	368
11.6	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	372
11.6.1	INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET	372
?		
11.7	ACADEMIC INSTITUTES	375
11.7.1	INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH	375
11.8	OTHER END USERS	378
12	IN VITRO DIAGNOSTICS MARKET, BY REGION	382
12.1	INTRODUCTION	383
12.2	NORTH AMERICA	383
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	384

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



12.2.2	US	392
12.2.2.1	Established reimbursement framework and favorable policies for IVD providers to drive market	392
12.2.3	CANADA	399
12.2.3.1	Favorable funding initiatives for early disease diagnosis to fuel market	399
12.3	EUROPE	405
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	406
12.3.2	GERMANY	413
12.3.2.1	Increasing investments in clinical diagnostics research to aid growth	413
12.3.3	FRANCE	418
12.3.3.1	High healthcare expenditure and rising investments in genomic medicine to drive market	418
12.3.4	UK	424
12.3.4.1	Rising adoption of genome-based testing to encourage growth	424
12.3.5	ITALY	430
12.3.5.1	Growing geriatric population and subsequent rise in chronic conditions to boost market	430
12.3.6	SPAIN	436
12.3.6.1	Increasing adoption of technologically advanced immunoassay systems to expedite growth	436
12.3.7	RUSSIA	441
12.3.7.1	High incidence of respiratory infectious diseases to boost market	441
12.3.8	SWITZERLAND	447
12.3.8.1	Growing prevalence of chronic diseases to propel market	447
12.3.9	REST OF EUROPE	453
12.4	ASIA PACIFIC	459
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	460
12.4.2	JAPAN	468
12.4.2.1	Increasing research investments for immunoassays to encourage growth	468
12.4.3	CHINA	473
12.4.3.1	Growing focus on preventive care to boost market	473
12.4.4	INDIA	479
12.4.4.1	Rising incidence of diabetes and cancer to augment growth	479
12.4.5	SOUTH KOREA	485
12.4.5.1	Rising healthcare spending for innovative IVD technologies to amplify growth	485
12.4.6	AUSTRALIA	491
12.4.6.1	Increasing incidence of chronic diseases and rising blood donations to fuel market	491
12.4.7	SINGAPORE	497
12.4.7.1	Rising technological advancements and automation to stimulate growth	497
12.4.8	REST OF ASIA PACIFIC	502
12.5	LATIN AMERICA	508
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	508
12.5.2	BRAZIL	514
12.5.2.1	Rising prevalence of diabetes to sustain growth	514
12.5.3	MEXICO	520
12.5.3.1	Growing establishment of clinical laboratories to fuel market	520
12.5.4	REST OF LATIN AMERICA	526
12.6	MIDDLE EAST & AFRICA	533
12.6.1	GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET	533
12.6.2	MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK	533
12.7	GCC COUNTRIES	538

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.7.1	GCC COUNTRIES: MACROECONOMIC OUTLOOK	539
12.7.2	SAUDI ARABIA	544
12.7.2.1	Rising government healthcare expenditure to boost market	544
12.7.3	UAE	550
12.7.3.1	Improvements in healthcare infrastructure to support growth	550
12.7.4	OTHER GCC COUNTRIES	555
13	COMPETITIVE LANDSCAPE	561
13.1	OVERVIEW	561
13.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	561
13.3	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS	562
13.4	REVENUE ANALYSIS, 2022-2024	563
13.5	MARKET SHARE ANALYSIS, 2024	564
13.6	COMPANY VALUATION AND FINANCIAL METRICS	566
13.7	BRAND/PRODUCT COMPARISON	567
13.8	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	568
13.8.1	STARS	568
13.8.2	EMERGING LEADERS	568
13.8.3	PERVASIVE PLAYERS	568
13.8.4	PARTICIPANTS	568
13.8.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	570
13.8.5.1	Company footprint	570
13.8.5.2	Region footprint	571
13.8.5.3	Product & service footprint	572
13.8.5.4	Technology footprint	573
13.8.5.5	End-user footprint	574
13.9	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	575
13.9.1	PROGRESSIVE COMPANIES	575
13.9.2	RESPONSIVE COMPANIES	575
13.9.3	DYNAMIC COMPANIES	575
13.9.4	STARTING BLOCKS	575
13.9.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	577
13.9.5.1	Detailed list of key startups/SMEs	577
13.9.5.2	Competitive benchmarking of key startups/SMEs	578
13.10	COMPETITIVE SCENARIO	579
13.10.1	PRODUCT LAUNCHES AND APPROVALS	579
13.10.2	DEALS	580
13.10.3	EXPANSIONS	581
13.11	POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET	582
13.11.1	PRODUCT LAUNCHES AND APPROVALS	583
13.11.2	DEALS	583
14	COMPANY PROFILES	585
14.1	KEY PLAYERS	585
14.1.1	DANAHER	585
14.1.1.1	Business overview	585
14.1.1.2	Products/Services offered	587
14.1.1.3	Recent developments	590
14.1.1.3.1	Product launches and approvals	590

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

14.1.1.3.2□Deals□591  
14.1.1.3.3□Expansions□592  
14.1.1.4□MnM view□593  
14.1.1.4.1□Key strengths□593  
14.1.1.4.2□Strategic choices□593  
14.1.1.4.3□Weaknesses and competitive threats□593  
14.1.2□F. HOFFMANN-LA ROCHE LTD□594  
14.1.2.1□Business overview□594  
14.1.2.2□Products/Services offered□596  
14.1.2.3□Recent developments□599  
14.1.2.3.1□Product launches and approvals□599  
14.1.2.3.2□Deals□601  
14.1.2.3.3□Expansions□602  
14.1.2.4□MnM view□602  
14.1.2.4.1□Key strengths□602  
14.1.2.4.2□Strategic choices□602  
14.1.2.4.3□Weaknesses and competitive threats□602  
14.1.3□ABBOTT□603  
14.1.3.1□Business overview□603  
14.1.3.2□Products/Services offered□604  
14.1.3.3□Recent developments□607  
14.1.3.3.1□Product launches and approvals□607  
14.1.3.3.2□Deals□608  
14.1.3.3.3□Expansions□609  
14.1.3.4□MnM view□609  
14.1.3.4.1□Key strengths□609  
14.1.3.4.2□Strategic choices□609  
14.1.3.4.3□Weakness and competitive threats□609  
14.1.4□SIEMENS HEALTHINEERS AG□610  
14.1.4.1□Business overview□610  
14.1.4.2□Products/Services offered□612  
14.1.4.3□Recent developments□614  
14.1.4.3.1□Product launches and approvals□614  
14.1.4.3.2□Deals□614  
14.1.4.3.3□Expansions□616  
14.1.4.4□MnM view□616  
14.1.4.4.1□Key strengths□616  
14.1.4.4.2□Strategic choices□616  
14.1.4.4.3□Weaknesses and competitive threats□616  
14.1.5□THERMO FISHER SCIENTIFIC INC.□617  
14.1.5.1□Business overview□617  
14.1.5.2□Products/Services offered□618  
14.1.5.3□Recent developments□621  
14.1.5.3.1□Product launches and approvals□621  
14.1.5.3.2□Deals□622  
14.1.5.3.3□Expansions□624  
14.1.5.4□MnM view□624

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.5.4.1	Key strengths	624
14.1.5.4.2	Strategic choices	624
14.1.5.4.3	Weaknesses and competitive threats	625
14.1.6	ILLUMINA, INC.	626
14.1.6.1	Business overview	626
14.1.6.2	Products/Services offered	628
14.1.6.3	Recent developments	629
14.1.6.3.1	Product launches and approvals	629
14.1.6.3.2	Deals	630
14.1.6.3.3	Expansions	631
14.1.6.3.4	Other developments	632
14.1.7	HOLOGIC, INC.	633
14.1.7.1	Business overview	633
14.1.7.2	Products/Services offered	634
14.1.7.3	Recent developments	635
14.1.7.3.1	Product launches and approvals	635
14.1.7.3.2	Deals	636
14.1.7.3.3	Expansions	637
14.1.8	BIO-RAD LABORATORIES, INC.	638
14.1.8.1	Business overview	638
14.1.8.2	Products/Services offered	640
14.1.8.3	Recent developments	642
14.1.8.3.1	Product launches and approvals	642
14.1.8.3.2	Deals	643
14.1.9	BIOMERIEUX	644
14.1.9.1	Business overview	644
14.1.9.2	Products/Services offered	646
14.1.9.3	Recent developments	648
14.1.9.3.1	Product launches and approvals	648
14.1.9.3.2	Deals	649
14.1.9.3.3	Expansions	650
14.1.10	SYSMEX CORPORATION	651
14.1.10.1	Business overview	651
14.1.10.2	Products/Services offered	653
14.1.10.3	Recent developments	654
14.1.10.3.1	Product launches and approvals	654
14.1.10.3.2	Deals	655
14.1.10.3.3	Expansions	656
14.1.11	REVVITY	657
14.1.11.1	Business overview	657
14.1.11.2	Products/Services offered	659
14.1.11.3	Recent developments	660
14.1.11.3.1	Product launches and approvals	660
14.1.11.3.2	Deals	661
14.1.11.3.3	Other developments	661
14.1.12	BECTON, DICKINSON AND COMPANY	662
14.1.12.1	Business overview	662

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.12.2	Products/Services offered	663
14.1.12.3	Recent developments	666
14.1.12.3.1	Product launches and approvals	666
14.1.12.3.2	Deals	666
14.1.12.3.3	Expansions	667
14.1.13	AGILENT TECHNOLOGIES, INC.	668
14.1.13.1	Business overview	668
14.1.13.2	Products/Services offered	670
14.1.13.3	Recent developments	672
14.1.13.3.1	Product launches and approvals	672
14.1.13.3.2	Deals	673
14.1.13.3.3	Other developments	674
14.1.14	QIAGEN	675
14.1.14.1	Business overview	675
14.1.14.2	Products/Services offered	677
14.1.14.3	Recent developments	680
14.1.14.3.1	Product launches and approvals	680
14.1.14.3.2	Deals	682
14.1.15	DIASORIN S.P.A.	683
14.1.15.1	Business overview	683
14.1.15.2	Products/Services offered	685
14.1.15.3	Recent developments	687
14.1.15.3.1	Product launches and approvals	687
14.1.15.3.2	Deals	688
14.1.16	GRIFOLS, S.A.	689
14.1.16.1	Business overview	689
14.1.16.2	Products/Services offered	691
14.1.16.3	Recent developments	691
14.1.16.3.1	Product launches and approvals	691
14.1.16.3.2	Deals	692
14.1.17	WERFEN	693
14.1.17.1	Business overview	693
14.1.17.2	Products/Services offered	695
14.1.17.2.1	Deals	696
14.1.17.2.2	Expansions	697
14.1.18	QUIDELORTHO CORPORATION	698
14.1.18.1	Business overview	698
14.1.18.2	Products/Services offered	700
14.1.18.3	Recent developments	702
14.1.18.3.1	Product launches and approvals	702
14.1.18.3.2	Deals	703
14.1.18.3.3	Expansions	703
14.2	OTHER PLAYERS	704
14.2.1	DEVYSER	704
14.2.2	BIOSYNEX SA	705
14.2.3	SURMODICS, INC.	706
14.2.4	MENARINI SILICON BIOSYSTEMS	707

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.2.5	SPEEDX PTY. LTD.	708
14.2.6	GENSPEED BIOTECH GMBH	709
14.2.7	MERCK KGAA	710
14.2.8	CARIS LIFE SCIENCES	712
14.2.9	ARKRAY, INC.	713
14.2.10	ACCELERATE DIAGNOSTICS, INC.	714
14.2.11	CELLABS	715
14.2.12	J. MITRA & CO. PVT. LTD.	716
14.2.13	EPITOPE DIAGNOSTICS, INC.	717
14.2.14	BOSTER BIOLOGICAL TECHNOLOGY	718
14.2.15	ENZO BIOCHEM INC.	719
14.2.16	GENETIC SIGNATURES	720
14.2.17	SAVYON DIAGNOSTICS	721
14.2.18	TRIVITRON HEALTHCARE	722
14.2.19	MDXHEALTH	723
14.2.20	CREATIVE DIAGNOSTICS	724
14.2.21	INBIOS INTERNATIONAL, INC.	725
14.2.22	MACCURA BIOTECHNOLOGY CO., LTD.	726
14.2.23	LUYE LIFE SCIENCES GROUP	727
15	APPENDIX	728
15.1	DISCUSSION GUIDE	728
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	735
15.3	CUSTOMIZATION OPTIONS	737
15.4	RELATED REPORTS	738
15.5	AUTHOR DETAILS	739

**In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global  
Forecast to 2030**

Market Report | 2025-05-09 | 740 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>